European Journal of Heart Failure

Article	Citations
	1675
Reply to ‘Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?’	281
Striving for the ‘perfect’ definition of iron deficiency in heart failure	156
Identifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow‐up	154
Letter regarding the article ‘Employment of artificial intelligence for an unbiased evaluation regarding the recovery of right ventricular function after mitral valve transcatheter edge‐to‐edge repair	141
Adrenomedullin as a marker of hypoxia, not hypoperfusion. Letter regarding the article ‘Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients h	129
Reply to the letter regarding the article ‘Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?’	129
Heart failure: age is no excuse for complacency	118
Expanding the horizon of medication adherence strategies in acutely decompensated heart failure. Letter regarding the article ‘Medication adherence in patients with acutely decompensated heart failure	110
Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery	105
Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE‐HF2 trial	103
Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: Size matters	101
Issue Information	101
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial	92
Cardiovascular magnetic resonance‐estimated pulmonary capillary wedge pressure, congestion markers, and effect of empagliflozin in patients with heart failure with reduced ejection fraction	92
Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials	81
Salt repletion and diuretic response: The role of serum chloride. A post‐hoc analysis of the SALT‐HF trial on furosemide and hypertonic saline solution administration in ambulato	81
Are left ventricular ejection fraction phenotypes meaningful in acute heart failure?	78
Issue Information	71
Association between liver fibrosis, plasma volume status, and cardiovascular mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases	70
Risk factors for the development of heart failure in patients with or without prior myocardial infarction	69
Abstract	67
Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long‐term survival	67
Similarities and distinctions between acetazolamide and sodium–glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE	67
Applying the ‘touch‐and‐go’ concept to mineralocorticoid receptor antagonists: A paradigm shift in routine heart failure management	66

Issue Information	65
Incidence and predictors of weaning failure from veno‐arterial extracorporeal membrane oxygenation therapy in patients with cardiogenic shock	64
Exercise catheterization in adults post‐Fontan with normal and abnormal haemodynamic criteria: Insights into normal Fontan physiology	64
Burst steroid therapy for acute heart failure: The CORTAHF randomized, open‐label, pilot trial	63
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON‐HF	62
Abstract	62
Clinical profiles and prognostic impact of residual intravascular and tissue congestion in acute heart failure	61
Decongestion strategies in patients presenting with acutely decompensated heart failure: A worldwide survey among physicians	61
Determinants of submaximal exercise intolerance in patients with heart failure and preserved ejection fraction: Insights from the lactate threshold	61
Culture, ethnicity, and socio‐economic status as determinants of the management of patients with advanced heart failure who need palliative care: A clinical consensus statement from the Heart Failure	60
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials	60
Dissecting the heart failure phenotype through phenomics	59
Corrigendum to ‘Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy’ [Eur J Heart Fail	59
Atrial cardiomyopathy: From healthy atria to atrial failure. A clinical consensus statement of the Heart Failure Association of the ESC	59
Time‐varying analyses of survival and outcomes in patients with HeartMate 3 left ventricular assist devices	59
Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology	59
Issue Information	57
The dangerous liaison between epicardial adipose tissue and heart failure with preserved ejection fraction	57
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial	57
July 2023 at a glance: heart failure with preserved ejection fraction and comorbidities	57
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial	57
Issue Information	55
Normal and excessive muscle sympathetic nerve activity in heart failure: implications for future trials of therapeutic autonomic modulation	55
Correction to “Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence a	55
Cardiopulmonary functional capacity: another piece of the puzzle of sodium–glucose cotransporter 2 inhibition in heart failure?	54
Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS‐HF trial	54
Reply to the letter regarding the article ‘Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care’	54
Letter regarding the article ‘Association between antecedent myocardial infarction and heart failure with preserved versus reduced ejection fraction’	54
December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models	52
	52
Predicting survival in patients with severe heart failure: Risk score validation in the HELP‐HF cohort	52
Aortic valve disease and heart failure with mildly reduced ejection fraction: New insights and pending questions	51
Corrigendum to ‘Congestion in heart failure: A circulating biomarker‐based perspective’ and articles listed below	51
Low blood pressure and the effect of empagliflozin in acute heart failure: An EMPULSE analysis	50
Letter regarding the article ‘Efficacy and safety of angiotensin receptor–neprilysin inhibition in heart failure patients with end‐stage kidney disease on maintenance dialysis: A systematic review and	50
404‐error “Disease not found”: Unleashing the translational potential of ‐omics approaches beyond traditional disease classification in heart failure research	49
Predicting worsening heart failure with preserved ejection fraction from non‐invasive exercise testing	49
Reply to ‘A clinical classification method with outstanding advantages for quickly identifying hazardous types’	48
Sex differences in the generalizability of randomized clinical trials in heart failure with reduced ejection fraction	47
Integrated trajectories of systolic and diastolic function differentially associate with risk for heart failure with preserved and reduced ejection fraction and proteomic profiles	47
Landscape of glycolytic metabolites and their regulating proteins in myocardium from human heart failure with preserved ejection fraction	46
The effect of intravenous ferric carboxymaltose on right ventricular function – insights from the IRON‐CRT trial	46
Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE‐HF trial	46
Remote patient management of heart failure across the ejection fraction spectrum: A pre‐specified analysis of the TIM‐HF2 trial	45
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis	45
The cost‐effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health‐economic analysis of the DELIVER trial	44
Indexing left ventricular end‐systolic dimension to body size: Association with mortality in patients with degenerative mitral regurgitation	44
Use of mechanical circulatory support in patients with non‐ischaemic cardiogenic shock	44
Revascularization in ischaemic heart failure with preserved ejection fraction: a nationwide cohort study	44
Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure	44

Heart failure improvement, remission, and recovery: A European Journal of Heart Failure	43
Health status across major subgroups of patients with heart failure and preserved ejection fraction	43
Cardiac autonomic neuropathy and risk of incident heart failure among adults with type 2 diabetes	43
Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced	43
Effect of long‐term tafamidis treatment on health‐related quality of life in patients with transthyretin amyloid cardiomyopathy	43
	42
Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium–glucose cotransporter 2 inhibitors	42
Serial direct sodium removal in patients with heart failure and diuretic resistance	42
Diagnostic pathways to wild‐type transthyretin amyloid cardiomyopathy: a multicentre network study	42
Systemic embolism in transthyretin amyloid cardiomyopathy: how to look into the future	42
The different risk of new‐onset, chronic, worsening, and advanced heart failure: A systematic review and meta‐regression analysis	42
Reply to the letter regarding the article ‘Head‐to‐head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines’	41
	41
Artificial intelligence in heart failure improving the efficiency or dependency on it? Letter regarding the article ‘Artificial intelligence and heart failure: A state‐of‐the‐art review’	41
The impact of early surgery on mortality in infective endocarditis complicated by heart failure – How much more data do we need?	41
Reply to ‘Sodium–glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction – lessons from clinical trials’	41
Delivering more evidence for the specificities of heart failure with improved ejection fraction: New answers, new questions	40
Supplement Article	40
	40
Managing water and salt balance in heart failure: Is there anything else to consider other than diet and diuretics?	40
An individual treatment effect approach to predict response to mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction	40
Late diagnosis in cancer sparks outrage—so why not heart failure?	40
Issue Information	40
Clinical trials: conventional or pragmatic?	40
Video thermography uncovers relationship between volume status and temperature in heart failure	39
Enrolling patients in cardiogenic shock trials: are we missing someone? Insights from the Italian AltShock‐2 registry	39
Application of a transthyretin amyloid cardiomyopathy score to heart failure with mildly reduced or preserved ejection fraction	39
Sodium–glucose cotransporter 2 inhibition, uric acid, and heart failure: correlation without causation?	39
Low‐dose digoxin improves cardiac function in patients with heart failure, preserved ejection fraction and atrial fibrillation – the RATE‐AF randomized trial	39
Predicting heart failure: The promise of proteomics	38
What's new in heart failure? October 2025	38
Revolutionizing cardiogenic shock treatment: Is the microaxial flow pump the ultimate game changer?	38
Withdrawn: Major gaps in the information provided to patients before implantation of cardioverter defibrillators: a prospective patient European evaluation	38
Reply to ‘Is sodium chloride supplementation ready for clinical practice in acute heart failure?’	38
More than just a clinical syndrome: Biomarkers and echocardiography should be rapidly advised for anyone with suspected heart failure!	38
Corrigendum to “Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction”	38
No longer from pillar to post: The first effective step in treating heart failure with preserved ejection fraction	37
Comparison of pulmonary congestion severity using artificial intelligence‐assisted scoring versus clinical experts: A secondary analysis of BLUSHED‐AHF	37
Letter regarding the article ‘Guideline‐directed medical therapy for heart failure in arrhythmia‐induced cardiomyopathy with improved left ventricular ejection fraction’	37
Decreased left ventricular ejection fraction is associated with increased mortality in sepsis: A retrospective cohort study	37
Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF	37
Acute heart failure care – a consensus series of an international experts' group	37
The utilization and impact of cardiovascular specialists on guideline‐directed medical scores: An analysis of a diverse, multi‐state, electronic health record‐based registry	36
Differential sex‐related effect of left ventricular ejection fraction trajectory on the risk of mortality and heart failure readmission following hospitalization for acute heart failure: A longitudina	36
Changes in mid‐regional pro‐adrenomedullin during treatment with sacubitril/valsartan	36
Analysing the accuracy of pressure measurements during exercise with pulmonary artery pressure sensors – Insights from the ACTION‐MEMS study	35
Heart failure after left atrial appendage occlusion: Insights from the LAAOS III randomized trial	35
Clonal haematopoiesis is associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy	35
Diuretics in pregnancy: Data from the ESC Registry of Pregnancy and Cardiac disease (ROPAC)	35
Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry	35
Biventricular cardiac power reserve in heart failure with preserved ejection fraction	35
Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence	35
Cost‐effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA‐HF and DELIVER data	34
Effect of pulmonary artery pressure‐guided management on outcomes of patients with heart failure outside clinical trials: A systematic review and meta‐analysis of real‐world evidence with the	34
Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial	34
Kidney injury in patients with heart failure‐related cardiogenic shock: Results from an international, multicentre cohort study	34
Long‐term survival after acute heart failure hospitalization: from observation to collaborative interventions	34
Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multic	34
Comparative effectiveness of sacubitril/valsartan versus angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved	34
Disproportionate exercise‐induced pulmonary hypertension in relation to cardiac output in heart failure with preserved ejection fraction: a non‐invasive echocardiographic study	33
Reporting quality of heart failure randomized controlled trials 2000–2020: Temporal trends in adherence to CONSORT criteria	33
Assessing health status after discharge for decompensated heart failure: a patient‐centred priority	33
Trends in heart failure mortality in Sweden between 1997 and 2022	33
The heart during iron deficiency: a non‐rechargeable battery?	33
Issue Information	33
Transcatheter edge‐to‐edge repair: fix the heart, heal the liver	33
Remote pulmonary artery pressure‐guided management of patients with heart failure: A clinical consensus statement of the Heart Failure Association (HFA) of the ESC	33
Issue Information	33
Cardiac reverse remodelling with vericiguat: Victory or no victory?	33
Reply to the letter regarding the article ‘Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure’	33
Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open‐label, randomized controlled trial	32
Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: A pilot randomized controlled trial	32
	32
Myocardial perfusion in cardiac amyloidosis	32
Sodium–glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: Treat the heart, cherish the kidney	32
Reply to the letter regarding the article ‘Lower extremity lymphatic flow is associated with diuretic response in acute heart failure’	32
Issue Information	32
Impact of age on clinical outcomes and response to serelaxin in patients with acute heart failure: An analysis from the RELAX‐AHF‐2 trial	32
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of	31
Contemporary insights into the epidemiology, impact and treatment of secondary tricuspid regurgitation across the heart failure spectrum	31

Measures of left atrial function predict incident heart failure in a low‐risk general population: the Copenhagen City Heart Study	31
Parvovirus B19 – more than a bystander in the prognosis of non‐ischaemic heart failure	31
Concomitant latent pulmonary vascular disease leads to impaired global cardiac performance in heart failure with preserved ejection fraction	31
Correction to ‘What's new in heart failure? May–June 2024’, ‘What's new in heart failure? June–July 2024’, ‘What's new in heart failure? August–September 2024’, ‘The month in heart failure! September	30
Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure	30
Clonal haematopoiesis of indeterminate potential is associated with progression of aortic valve stenosis	30
Heart failure hospitalizations and clinical outcomes in patients undergoing tricuspid transcatheter edge‐to‐edge repair: Insights from EuroTR	30
Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA‐HF and DELIVER	30
Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency	30
End‐organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure‐2 (RELAX‐AHF‐2)	29
Plasma soluble fms‐like tyrosine kinase‐1, placental growth factor, and vascular endothelial growth factor system gene variants as predictors of survival in heart failure	29
Preventive catheter ablation for ventricular arrhythmias in patients with end‐stage heart failure referred for heart transplantation evaluation: Rationale for and design of the CASTLE‐	29
The addition of vericiguat to sacubitril/valsartan improved the composite endpoint. Add a finishing touch on heart failure medical therapy by vericiguat as secret ingredient	29
Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy	29
On‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of TRANSFORM‐HF	28
Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fraction	28
Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta‐analysis	28
Lung ultrasound and mortality in a cardiogenic shock population: A prospective registry‐based analysis	28
Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM‐HFpEF)	28
European Society of Cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension. Developed in collaboration with the Heart Failure Associatio	28
Evolocumab has no effects on heart failure with reduced ejection fraction injury biomarkers: The EVO‐HF trial	28
Management of patients with heart failure at high risk of hyperkalaemia: The CARE ‐ HK in	28
Clinical features, haemodynamics, and outcomes of heart failure with preserved ejection fraction in coarctation of aorta	28
Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases	28
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial	27
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the	27
Growth differentiation factor‐15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program	27
Early changes in renal function during rapid up‐titration of guideline‐directed medical therapy following an admission for acute heart failure	27
When is the time right? Dancing on the tightrope: referral for upgrade to cardiac resynchronization therapy	27
Implementing the evidence – the true summit of evidence‐based care and the false peak of guidelines	27
Sodium chloride supplementation in acute heart failure: A closer look at SOLVRED‐AHF. Letter regarding the article ‘Sodium chloride versus glucose solute as a volume replacement	27
Effect of allogeneic adipose tissue‐derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction – the SCIENCE trial	27
Reply to ‘Epicardial adipose tissue: does it mediate the cardio‐protective effects of sodium–glucose co‐transporter 2 inhibitors in subjects with heart failure?’ Letter regarding the article ‘Impact o	27
Reply to the letter regarding the article ‘Acute heart failure after non‐cardiac surgery: incidence, phenotypes, determinants and outcomes’	27
Is it NICE to measure natriuretic peptides after a hospitalization for heart failure?	27
Improve heart function to improve heart failure outcomes: the disease‐modifying effects of spironolactone	27
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial	27
When and how? Two simple questions to determine cancer status and inform therapeutic decisions and trial design in heart failure	27
If a patient does not require treatment with loop diuretics, do they really have heart failure?	26
Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial	26
The role of kidney disease progression in heart failure prognosis: Bridging the evidence gap for optimal management	26
Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61	26
Time to treat the climate and nature crisis as one indivisible global health emergency	26
Time to reconsider the perception and management of hypertensive heart disease	26
Bug attack! The rising importance of Chagas disease	25
Pulmonary vascular disease in heart failure with preserved ejection fraction: the evidence grows	25
Peri‐procedural management of transcatheter mitral valve replacement in patients with heart failure	25
Reply to the letter regarding the article ‘Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta‐analysis’	25
Pacing beyond rhythm – improving myocardial function by tickling the heart electrically?	25
Underestimation of congestion in very obese heart failure with preserved ejection fraction patients: EAT your heart out…?!	24
Growth differentiation factor‐15: A promising biomarker for early detection of pre‐heart failure	24
Letter regarding the article ‘Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT‐CHF (European) study with th	24
Impact of misclassification bias on interpretation of finerenone efficacy in chronic obstructive pulmonary disease and heart failure with mildly reduced or preserved ejection fraction: A critical appr	24
Changes in natriuretic peptide levels following patiromer‐enabled optimization of medical therapy in heart failure: A post hoc analysis of the DIAMOND study	24
A second wind for digitalis glycosides in heart failure?	24
Prioritizing prevention of de novo and worsening chronic heart failure	24
Transthyretin amyloidosis: the picture is getting clearer	24
Artificial intelligence methods for improved detection of undiagnosed heart failure with preserved ejection fraction	24
Splanchnic nerve block with botulinum toxin for therapy of chronic heart failure – mechanism of action (SPONGE‐HF)	24
Heart failure treatment in the last years of life: A nationwide study of 364 000 individuals	23
Tricuspid regurgitation: Frequency, clinical presentation, management and outcome among patients with severe left‐sided valvular heart disease in Europe. Insights from the ESC‐EORP Valvular	23
Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Reduced	23
Skeletal muscle and subcutaneous fat quantity as prognostic indicators in cardiac amyloidosis	23
Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge‐to‐edge repair – Results from the TriValve	23
Albuminuria as a diagnostic criterion and a therapeutic target in heart failure and other cardiovascular disease	23
Right heart failure as a cause of pulmonary congestion in pulmonary arterial hypertension	23
Guideline‐directed medical therapy for heart failure in arrhythmia‐induced cardiomyopathy with improved left ventricular ejection fraction	22
Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes	22
Issue Information	22
Reply to: ‘What is the optimal dose of neurohormonal modulators in patients with heart failure? The higher the better?’	22
Safety and performance of a novel implantable sensor in the inferior vena cava under acute and chronic intravascular volume modulation	22
Device‐based remote monitoring strategies for congestion‐guided management of patients with heart failure: a systematic review and meta‐analysis	22
A Heart Team approach to contemporary device decision‐making in heart failure	22
Worsening heart failure comes into focus, chronic heart failure takes a backseat	22
Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm A	22
A machine‐learning‐based prediction model in patients with takotsubo syndrome: ‘You can't stop change any more than you can stop the suns from setting!’	22
	21
Letter regarding the article ‘Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure’	21
Epicardial adipose tissue: does it mediate the cardio‐protective effects of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure? Letter regarding the article ‘Impact of epicardia	21
Time for differential weight management in heart failure	21
Persistent high mortality in acute myocardial infarction‐associated cardiogenic shock despite early mechanical circulatory support: Need for stepwise and integrated approach of care	21
Heart failure related central sympathetic activation: debunking the ‘holy grail’?	21
Clustering in dilated cardiomyopathy at initial evaluation: An effective tool for clinical stratification	21
Glucagon‐like peptide‐1 receptor agonists across the cardiovascular‐kidney‐metabolic spectrum: One size does not fit all	21
Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial	21
New cardiovascular biomarkers in patients with advanced cancer – A prospective study comparing MR‐proADM, MR‐proANP, copeptin, high‐sensitivity troponin T a	21
	21
Defining changes in physical limitation from the patient perspective: insights from the VITALITY‐HFpEF randomized trial	21
Giant cell myocarditis after first dose of BNT162b2 – a case report	21
A clinical classification method with outstanding advantages for quickly identifying hazardous types	21
Acute dyspnoea in cancer patients: Prevalence of acute heart failure, resource use and diagnostic accuracy of natriuretic peptides	21
Kidney involvement in transthyretin cardiac amyloidosis – Role of urinary albumin to creatinine ratio and need for further evidence generation	21
Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED‐AHF): A prospective, randomized, mechanistic	20
The chloride paradigm shift in heart failure: From neglected ion to keystone of precision diuretic therapy	20
Left ventricular transthyretin amyloid load and apical sparing in patients with newly confirmed transthyretin amyloid cardiomyopathy	20